Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADTX Aditxt	$1.03 -1.9%	$1.26	$0.81 ▼ $11,700.00	$2.18M	1.5	1.61 million shs	171,199 shs
BIOR Biora Therapeutics	$0.15 +6.5%	$0.14	$0.15 ▼ $7.10	$660K	1.12	86,634 shs	16,292 shs
CANF Can-Fite BioPharma	$0.68 -1.8%	$0.95	$0.63 ▼ $3.12	$2.39M	1.02	212,430 shs	96,492 shs
VAXX Vaxxinity	$0.00 -99.8%	$0.01	$0.00 ▼ $0.15	$13K	-24.16	6,463 shs	225,081 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADTX Aditxt	+1.94%	-3.67%	-11.76%	-34.78%	-99.99%
BIOR Biora Therapeutics	0.00%	0.00%	0.00%	+8.07%	-97.82%
CANF Can-Fite BioPharma	+4.29%	+0.42%	-33.43%	-34.13%	-72.69%
VAXX Vaxxinity	-2.33%	+41,900.00%	+41,900.00%	+320.00%	+110.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADTX Aditxt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BIOR Biora Therapeutics	2.0434 of 5 stars	3.5	0.0	0.0	0.0	0.6	2.5	0.6
CANF Can-Fite BioPharma	1.7858 of 5 stars	3.5	2.0	0.0	0.0	0.6	0.0	1.3
VAXX Vaxxinity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADTX Aditxt	0.00	N/A	N/A	N/A
BIOR Biora Therapeutics	3.00	Buy	$23.00	15,664.22% Upside
CANF Can-Fite BioPharma	3.00	Buy	$14.00	1,971.01% Upside
VAXX Vaxxinity	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest BIOR, ADTX, VAXX, and CANF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/29/2025	CANF Can-Fite BioPharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADTX Aditxt	$130K	16.80	N/A	N/A	($1.52) per share	-0.68
BIOR Biora Therapeutics	$892K	0.74	N/A	N/A	($36.43) per share	0.00
CANF Can-Fite BioPharma	$674K	3.55	N/A	N/A	$1.76 per share	0.38
VAXX Vaxxinity	N/A	N/A	N/A	N/A	$0.11 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADTX Aditxt	-$34.45M	N/A	0.00	∞	N/A	-46,082.47%	-389.10%	-84.71%	8/18/2025 (Estimated)
BIOR Biora Therapeutics	-$124.11M	-$13.04	N/A	N/A	N/A	N/A	N/A	-332.47%	N/A
CANF Can-Fite BioPharma	-$7.63M	-$1.79	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VAXX Vaxxinity	-$56.93M	-$0.45	N/A	∞	N/A	N/A	N/A	N/A	N/A

Latest BIOR, ADTX, VAXX, and CANF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/15/2025	Q1 2025	ADTX Aditxt	-$26,400.00	-$8.12	+$26,391.88	-$8.12	$0.43 million	$0.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADTX Aditxt	N/A	N/A	N/A	N/A	N/A
BIOR Biora Therapeutics	N/A	N/A	N/A	N/A	N/A
CANF Can-Fite BioPharma	N/A	N/A	N/A	N/A	N/A
VAXX Vaxxinity	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADTX Aditxt	N/A	0.08	0.08
BIOR Biora Therapeutics	N/A	0.05	0.05
CANF Can-Fite BioPharma	N/A	2.93	N/A
VAXX Vaxxinity	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADTX Aditxt	15.54%
BIOR Biora Therapeutics	43.74%
CANF Can-Fite BioPharma	21.00%
VAXX Vaxxinity	82.95%

Insider Ownership

Company	Insider Ownership
ADTX Aditxt	0.01%
BIOR Biora Therapeutics	51.08%
CANF Can-Fite BioPharma	0.80%
VAXX Vaxxinity	64.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADTX Aditxt	60	2.12 million	2.12 million	No Data
BIOR Biora Therapeutics	120	4.52 million	2.21 million	Optionable
CANF Can-Fite BioPharma	8	3.54 million	N/A	Not Optionable
VAXX Vaxxinity	90	126.75 million	45.55 million	Not Optionable

BIOR, ADTX, VAXX, and CANF Headlines

Recent News About These Companies

Brain health

October 24, 2024 | newsweek.comN

Treatment Trials in Alzheimer's Disease

September 30, 2024 | msn.com

Is Vaxxinity Inc (VAXX) Stock a Good Investment?

September 19, 2024 | aaii.comA

Congress makes $4.5 trading stocks in a day; Here's the biggest winners

July 4, 2024 | finbold.comF

Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine

June 20, 2024 | globenewswire.com

Why Is Vaxxinity (VAXX) Stock Up 39% Today?

May 3, 2024 | investorplace.com

Why Is Vaxxinity (VAXX) Stock Down 58% Today?

April 22, 2024 | investorplace.com

Vaxxinity Plans to Delist Shares From Nasdaq

April 19, 2024 | marketwatch.com

Vaxxinity Issues Shareholder Letter

April 19, 2024 | globenewswire.com

Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

April 19, 2024 | globenewswire.com

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

March 28, 2024 | globenewswire.com

VAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023

March 27, 2024 | investorplace.com

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

March 27, 2024 | globenewswire.com

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024

March 7, 2024 | globenewswire.com

Vaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol Levels

February 15, 2024 | finance.yahoo.com

Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

February 15, 2024 | finance.yahoo.com

Vaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

February 15, 2024 | globenewswire.com

Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024

February 13, 2024 | finance.yahoo.com

Vaxxinity, UF Join Forces Against Neurodegenerative Diseases

January 30, 2024 | finance.yahoo.com

Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida

January 30, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOR, ADTX, VAXX, and CANF Company Descriptions

Aditxt NASDAQ:ADTX

$1.03 -0.02 (-1.90%)

Closing price 04:00 PM Eastern

Extended Trading

$1.03 0.00 (0.00%)

As of 04:17 PM Eastern

Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

Biora Therapeutics NASDAQ:BIOR

Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

Can-Fite BioPharma NYSE:CANF

$0.68 -0.01 (-1.79%)

Closing price 03:57 PM Eastern

Extended Trading

$0.68 0.00 (-0.15%)

As of 04:10 PM Eastern

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

Vaxxinity NASDAQ:VAXX

$0.0001 -0.04 (-99.76%)

As of 12:56 PM Eastern

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time